Concord Biotech Ltd.NSE: CONCORDBIO

CONCORDBIO: Strong revenue growth and stable profits, with a one-time charge for regulatory changes

· Issued by Concord Biotech Ltd.

Revenue and net profit grew year-over-year for both standalone and consolidated results, with a one-time exceptional charge for new Labour Codes. A new Company Secretary was appointed, and no audit qualifications or loan defaults were reported.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Concord Biotech Ltd. on 6ix

In the deck

Earlier from Concord Biotech

Later from Concord Biotech

All Concord Biotech news releases